AstraZeneca to sequence 2 million genomes – partnering with the University of Helsinki


International pharmaceutical company AstraZeneca has announced to invest widely in genome research in the near future. As a part of the initiative, AstraZeneca is partnering with University of Helsinki, Institute for Molecular Medicine for utilizing Finnish genome and health data in drug development.
Research project is based on theTHL Biobank and the University of Helsinki sample collections and the collaboration with Broad Institute of MIT and Harvard.
Read more (Nature News)